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Summary 
As a result of the selective screening worldwide during the last 18 years, approximately 250 patients 
with tetrahydrobiopterin deficiency were discovered. Most patients suffer from 6-pyruvoyl tetrahydropterin 
synthase deficiency (58%), followed by dihydropteridine reductase deficiency (35%), GTP cyclohydrolase 
I deficiency (3%), and "primapterinuria" (4%). The patients can be treated with neurotransmitter precursors, 
as well as with tetrahydrobiopterin. However, data on long term treatment are still scarce and it is therefore 
of great value to investigate all newborns with even mild hyperphenylalaninemia. Cloning of the enzymes 
involved in the biosynthesis and regeneration of tetrahydrobiopterin makes them to be easily accessible 
for biochemical and biological studies. So far, all proteins expressed heterologous are active in E. coli. 
Cloning of the wild type gene and mutant analysis of patients allow the rapid identification of the defective 
gene on the molecular level. 
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In troducti on 
Early detection of tetrahydrobiopterin (BH4) defi-
ciency became essential soon after it was recognized 
that a number of patients with hyperphenylalanin-
emia (HPA) show progressive neurological illness de-
spite treatment with a low-phenylalanine diet (I. 2). 
The disease was initially named "malignant phenyl-
ketonuria (PKU)" because some of these patients 
died early. The first patients with BH4 deficiency 
were described as "a genetic variant of PKU" (3) 
and were later characterized as suffering from a de-
fect in the regeneration of BH4. BH4 is known to 
be the natural cofactor of three aromatic amino acid 
oxidase: phenylalanine-4-hydroxylase (PAH). tyro-
sine-3-hydroxylase. and tryptophan-5-hydroxylase. 
PAH is responsible for the conversion of phenylala-
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nine to tyrosine: tyrosine-3-hydroxylase and trypto-
phan-5-hydroxylase are the rate-limiting enzymes in 
the biosynthesis of catecholamines and serotonin, 
respectively (4). Thus. any defect in the biosynthesis 
or regeneration of BH4 will result in a deficiency 
of biogenic amine neurotransmitters accompanied 
by HPA. 
About 250 patients with BH4 deficiency were dis-
covered world-wide in the last 18 years (5,6). Be-
cause of the different clinical and biochemical seve-
rity, this group of diseases was originally named "atyp-
ical PKU". a term which today is reserved for mild 
forms of PAH deficiency. 
Although a wide range of metabolic defects may 
exist, the term "typical" or "atypical" form will be 
used according to the actual need to treat, or not 
to treat, the patients. 
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Figure 2. Phenylalanine hydroxylating system including possi-
hie metabolic defects in hyperphenylalaninemia ( Ii' ). PAH: 
phenylalanine-4-hydroxylase: DHPR: dihydropteridine reduc-
tase: PHS/ PCD: PAH stimulating protein/pterin-4a-carhinol-
amine dehydratase. 
Biochemical observation 
So far four molecular diseases have been known 
to cause HPA including the classic form with a 
defect in the apoenzyme of PAH. Patients with the 
3 variants suffer primarily from BH4 deficiency, ei-
ther by one of the two defects in the biosynthesis 
(Fig. I) or one in regeneration (Fig. 2) of the cofac-
tor (7). They are all inherited autosomal recessive. 
In GTP cyclohydrolase I (GTPCH) deficiency (8), 
the enzyme catalyzing the first step in the biosyn-
thesis of BH4 is deficient and no pterins are synthe-
sized. These patients are characterized by a neopte-
rin and biopterin deficiency. Although it has been 
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Figure 3. Results of the screening for tetrahydrohiopterin dcti-
ciency collected from the international register. 
claimed that neopterin may play an active role in 
the cell-mediated immune response, cell prolifera-
tion, and differentiation, in one of these patients all 
humoral and cellular functions tested were found 
to be normal. In cerebrospinal fluid (CSF) neopte-
rin, biopterin, isoxanthopterin, pterin, as well as the 
neurotransmitter metabolites, homovanillic acid 
(HV A) and 5-hydroxyindoleacetic acid (5HIAA), 
were generally low. This enzyme deficiency is rare, 
with 7 patients detected so far (Fig. 3). 
6-Pyruvoyl-tetrahydropterin synthase (PTPS) defi-
ciency (9) is the most common and heterogeneous 
variant with about 144 patients diagnosed all over 
the world, corresponding to about 58% of all patients 
with a BH4 deficiency (Fig. 3). Patients with severe, 
partial or peripheral, and transient forms have been 
reported (10). 7,8-Dihydroneopterin triphosphate can 
not be converted to 6-pyruvoyl tetrahydropterin (Fig. 
1), resulting in an accumulation of 7,8-dihydroneo-
pterin triphosphate in tissue of these patients. This 
intermediate is readily dephosphotylated by pyro-
phosphatase and excreted as dihydroneopterin and 
its oxidation product, neopterin. High concentrations 
of neopterin, monapterin (isomer of neopterin), and 
3' -hydroxysepiapterin, and only traces of biopterin 
are found in the urine of the patients with PTPS 
deficiency. In servere (typical) forms of PTPS defi-
ciency the neurotransmitter status in the CSF is sim-
ilar to that in patients with GTPCH deficiency. 
In the peripheral or partial (atypical) forms of PTPS 
deficiency, normal levels of neurotransmitter meta-
bolites are measured. It is therefore of practical im-
portance to find out whether or not the patient be-
longs to this type of PTPS deficiency and thus may 
need different treatment (see below). The transient 
form of PTPS deficiency may be due to a matura-
tion delay of BH4 biosynthesis. 
In dihydropteridine reductase (DHPR) deficiency 
(II), the second most common form of BH4 deficien-
cy (88 patients detected; Fig. 3), quinonoid-dihyd-
robiopterin formed during the hydroxylation of 
phenylalanine to tyrosine accumulates, and the 
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amount of BH4 synthesized on the de novo pathway 
is insufficient for the normal function of hepatic 
PAH (Fig. 2). Similarly, as in the case of PTPS 
and GTPCH deficiencies, these patients are mostly 
characterized by a depletion of catecholamines and 
serotonin (12). Since quinonoid-dihydrohiopterin 
tautomerized readily to 7,8-dihydrohiopterin, patients 
with DHPR deficiency excrete high amounts of total 
bioptelin (7,8-dihydrohiopterin and hiopterin). In 
addition, owing to the lack of BH4 in these patients, 
there is no feedback inhihition of GTPCH and thus 
neopterin biosynthesis is generally activated. 
Primapterinuria is the recently discovered valiant 
of HPA characterized hy the excretion of the 7-sub-
stituted pterins, primapterin (7-biopterin) and ana-
pterin (7-neopterin) in the patient's urine (13, 14). Prima-
pterinuria differs from classic PKU and other vari-
ants of BH4 deficiency because obviously these pa-
tients do not need any treatment. Nine patients have 
been detected so far (Fig. 3). The first patients were 
described by Dhondt et al. (IS) and Blaskovics and 
Giudici (16). A loading test with BH4 was the first 
indication that primapterin may derive from biopte-
rin (17). Furthermore, 7,8-dihydrobiopterin and se-
piapterin given orally resulted in a significant in-
crease in biopterin and primapterin., whereas the ratio 
remained between 1.0 and I.S after loading (\8). 
From in vitro experiments it is known that plima-
pterin can be formed during the PAH reaction in 
a phenylalanine-4-hydroxylase-stimulating protein 
(PHS)/pterin-4a-carbinolamine dehydratase (PCD) 
free system (Fig. 2) (19,20). So far, all known en-
zymes involved in the biosynthesis or regeneration of 
BH4 in . these patients have been found to be normal 
and a deficiency of PHS/PCD has been proposed. 
However, PAH and PHS/PCD, per se, have not 
been measured. 
Clinical observation 
Typical .limns 
The clinical course of the illness in untreated pa-
tients is similar in typical (severe) PTPS, DHPR and 
GTPCH deficiencies (10). The median age at which 
clinical signs become evident is 4-S months, but symp-
toms do not necessarily correlate with age of di-
agnosis, even in the same family. However. when in-
fom1ation on the neonatal period is available, abnor-
mal signs (poor sucking, decreased spontaneous 
movements, floppy baby) can be noticed during the 
neonatal period (6). 
The common symptoms are mental retardation, 
convulsions (grand mal or myoclonic attacks), distur-
bances of tone and posture, drowsiness, irritahility, 
abnormal movements, recurrent hyperthermia with-
out infection, hypersalivation, swallowing difficul-
ties. Diunml fluctuation of alertness and neurologic 
symptoms are also reported. Microcephaly is observ-
ed in both diseases but with a higher incidence 
in PTPS deficiency (S2%) than in DHPR deficiency 
(33%). However, in 13 out of 2S DHPR deficient 
patients for whom repeated measurements with in-
creasing age were available, evolution of head circum-
ference to progressive microcephaly was observed, 
whether patients were treated or not. 
Arypical forms 
Atypical PTPS deficiency: The absence of clinical 
signs theoretically defines atypical forms. However, 
in 2 cases neonatal hypotonia was noticed, 2 were 
mentally retarded, 1 had local signs on the EEG, 
and I presented with acute but transient symptoms 
(behaviour prohlems. neurovegetative signs, sleeping 
difficulties). 
Atypical DHPR deficiency Some authors have sugges-
ted that partical deficiency of DHPR activity may 
also exist. That may explain a few reports on pa-
tient"; who were clinically unusual in some aspects (21). 
Primapterinuria: Although this fom1 seems to have 
no serious consequences. minor abnormalities can 
be observed. In the first case (IS). slight tremors 
of upper limhs after stimulations and a moderate 
tendency to hypertonia were noticed during the neo-
natal period. An EEG at 3 weeks of age revealed 
a few spikes and sharp waves in the frontal area. 
With dietary control of blood phenylalanine. neuro-
logical development normalized. In another case rc-
ported by Blaskovics and Guidici (16), transient hy-
potonia and motor delay were also noticed. 
Treatment 
The goals of the treatment are to control HPA 
by dietary restriction of phenylalanine or BH4 admin-
istration, and to restore neurotransmitter homeosta-
sis by oral administration of amine precursors. 
Neurotransm iner replacement 
L-Dopa and S-hydroxytryptophan (S-HT) admini-
stration represents a common therapeutic approach 
to BH4 deficiencies. Carbidopa, an inhibitor of peri-
pheral aromatic amino acid decarboxylase, reduces 
the therapeutic dose of L-Dopa. 
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The monitoring of treatment represents the crucial 
point. Unfortuntely, there are no biochemical para-
meters measurable in the periphery which would 
allow the control of treatment. The analysis of neu-
rotransmitter metabolites in CSF represents the only 
way to follow up the efficiency of treatment (Fig. 
4). However. such an investigation cannot be easily 
repeated. Two cases (Fig. 5) illustrate the need of 
a balanced administration of Dopa and 5-HT. 
In practice, the optimal dosage can only be found 
on a clinical basis and should be adjusted to the 
requirement of each patient with monitoring for ad-
verse effects (22, 23) and disappearance of neurolo-
gical symptoms. Diurnal fluctuations are often obser-
ved and may require changes in the schedule of 
drug administration. Difficulties with parents for com-
pliance with treatment are frequently reported be-
cause of the constant need of treatment adjustments. 
which requires excellent collaboration with the fam-
ily. 
Control of blood phenylalanine levels 
Although BH4 deficient persons exhibit a higher 
dietary phenylalanine tolerance than classical PKU 
patients. a limiting factor in tne response to neuro-
transmitter precursor therapy might be the plasma 
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Figure 5. CSt-' monitoring of the treatment with neurotrans-
mitter precursors. 
phenylalanine fluctuations. which could alter the 
dose-effect relationships of these substances by inter-
fering with their membrane transport or by compe-
titive inhibition of tyrosine and tryptophan-hydrox-
ylase (12). The control of blood phenylalanine concen-
trations has to be stricter than in other HPAs. Some 
patients on neurotransmitter treatment have had 
neurological problems with phenylalanine concent-
rations as low as 360 Ilmolll. 
Tetrahydrobiopterin admini~tra[ion 
In PTPS deficiency. evidence of a bloc in BH4 
synthesis invited attempts to treat these patients with 
BH4 replacement alone (so-called BH4 monothe-
rapy). The main advantage was that BH4 replace-
ment would not bypass any regulatory mechanisms 
that normally control neurotransmitter synthesis and 
secretion. However, in most cases BH4 monotherapy 
failed to restore a normal level of cerebral neurotrans-
mitter synthesis as confirmed by low concentra-
tio.ns of SHIAA and HVA in the CSF (Fig. 4). 
On the other hand. the use of BH4 to control blood 
phenylalanine levels appears to be efficient and is 
recommended. Relatively low doses of BH4 normal-
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ize blood phenylalanine levels and offer an interest-
ing alternative to a phenylalanine-restricted diet. 
In DHPR deficiency, BH4 cannot be given in suf-
ficient amounts to maintain an adequate pool of 
BH4 in the absence of the endogenous reducing sys-
tem sustained by DHPR. 
Folinic acid supplementation 
The hypothesis of a gradual CNS folate deficiency 
in DHPR deficienct patients is supported by low 
CSF folate levels, and also by the frequent occur-
rence of calcifications in the basal ganglia similar to 
those described in congenital folate malabsorption 
or in methotrexate toxicity. A direct benefit of folinic 
acid supplementation has been clinically demon-
strated (24). 
The clinical outcome 
The replacement of neurotransmitters has been 
proven to be beneficial, though incomplete. Because 
in many cases the treatment was administered late, 
resolution of some of the major neurological signs 
gave the impression of a "remarkable" improvement, 
as initially published. Even when patients reached 
milestones for age. speech difficulties and sleeping 
problems were reported. Two PTPS and 6 DHPR 
deficient patients died although the treatment had 
been started within the first month of life. 
Although results of a larger group of patients treat-
ed early might temper these pessimistic conclusions, 
four reasons can explain the limited success of treat-
ment: 
I. The possibility of fetal brain damage is likely 
to occur, especially in PTPS deficiency, since low 
birth weight, clinical signs. and microcephaly at 
birth are often reported. 
2. Possible iatrogenic damage of neurotransmitter 
precursors cannot be excluded. 
3. It can also be speculated that the quality of the 
response to therapy depends on the severity of the 
metabolic defect, as illustrated by the better response 
of patients with near normal CSF HV A concentra-
tions at diagnosis (25). In DHPR deficiency, it has 
also been suggested that CRM + mutants may have 
a better prognosis (26). 
Do atypical fonns have to be treated? 
These forms theoretically do not require treatment. 
Besides this affirmation, the decision to treat or not 
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the differentiation of hyperphenylalaninemia variants. if re-
presents increased value; .(), represents deminished value. Phe: 
phenylalanine; Tyr: tyrosine; AA amino acids; Nco: neopterin: 
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is not clear-cut. With regard to the obvious hetero-
geneity and unclear prognosis it seems adequate to 
treat newborns with the so called "atypical" or "peri-
pheral" form, at least with BH4, and to monitor their 
development carefully. 
Screening for BIL deficiency and differential diagno-
sis 
Screening for BH4 deficiency should be done in 
all newborns with even slight hyperphenylalanine-
mia (plasma phenylalanine<400 f.1IIlol//) as well as 
in older children with neurological symptoms (27, 
28). The following protocol should be followed: 
1. Analysis of pterins in urine 
2. Measurement of DHPR activity in blood from 
Guthrie cards 
3. Analysis of phenylalanine in plasma before and 
after the BH4 loading test 
The first two tests are essential and allow to differ-
entiate between all variants of BH4 deficiency. With 
some limitations, the BH4 loading test is an addition-
al useful diagnostic tool for the rapid discrimination 
between the classic PKU and biopterin variants. The 
diagnostic flow-chart is shown in Fig. 6. 
Analysis oj pterins 
HPLC is the method which is used in most labo-
ratories to analyze pterins in urine (29, 30). The 
analysis must be performed at elevated plasma phe-
nylalanine levels and not under low-phenylalanine 
diet. Either a native urine or urine dried on filter 
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ninemia. N: neopterin : M: monapterin; IX: isoxanthopterin: 
B: biopterin: 7-B: primapterin; P: pterin. 
paper (31) may be used for the selective screening. 
The concentrations of pterins are based on creati-
nine levels, which makes a urine collection unneces-
sary. A characteristic urinary pterin pattern makes 
it possible to identify all four variants of BH4 defi-
ciency (Fig. 7). 
Tn GTPCH deficiency, neopterin and biopterin 
excretion is extremely low (below 10% of normal) 
while the percentage of biopterin (of the sum of 
neopterin plus biopterin) is approximately 50% (neo-
pterin/biopterin~ 1). Patients with PTPS deficiency 
excrete trace amounts of biopterin and high amounts 
of neopterin (biopterin <5%; neopterin/biopterin = 
40-300). Excretion of pterins is not always infor-
mative for DHPR deficiency. High biopterin concen-
trations (biopterin>80%) and normal or slightly in-
creased neopterin concentrations are rather charac-
teristic for older children suffering from DHPR defi-
ciency and particularly in very young patients may 
be almost normal or close to values found in patients 
with classic PKU In patients with primapterinuria 
the pterin pattern is similar to that in patients with 
PTPS deficiency (elevated neopterin and low biopte-
rin; neopterin/biopterin= 18-36) in the very early 
neonatal period. With increasing age neopterin nor-
malizes while the excretion of primapterin persists 
and the ratio of biopterin to primapterin remains 
close to 1. 
Loading test with BH4 
The loading test with BH4 allows the detection 
of all HPA variants with a defect of the BH4 biosyn-
thesis, even if the defect is only partial. A rapid 
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Figure 8. Typical results of a simple (A) and combined (B) 
tetrahydrobiopterin loading tests in patients with hyperphen-
ylalaninemia. 
normalization of the elevated plasma phenylalanine 
level occurs within 4 to 8 hours after administration 
of BH4 (Fig. 8A). The test was originally introduced 
by Niederwieser el al.(32) using 7.5 mg of BHJkg 
bw. However, it was soon noted that this procedure 
may fail in some patients with DHPR deficiency 
(26), namely those belonging to the CRM + (cross 
reactive material positive) type having a mutant en-
zyme. This limitation can be overcome by increasing 
the loading dose up to 20 mg BHJkg bw . . However 
one patient, described as a nonresponder even at 
high dose of BH4, died despite early diagnosis and 
treatment and may represent a "severe" form of 
DHPR deficiency (33). 
An alternative procedure for the screening of hy-
perphenylalaninemiae is the combined phenylala-
nine (100 mg/kg bw) and BH4 (20 mg/kg bw) load-
ing test (34). This test takes advantage of being 
performed while patients are on a phenylalanine-res-
tricted diet particularly when pterin analysis is not 
available. As for the conventional loading test, this 
also has to be combined with the measurement of 
DHPR activity in blood. The decrease of serum 
phenylalanine 4 and 8 hours after BH4 administra-
tion (7 and 11 hours after phenylalanine admini-
stration) allows differentiation between PTPS and 
DHPR deficiencies and classic PKU (Fig. 8B). 
Molecular biology of BlL biosynthetic and regenera-
ting enzymes: gene cloning and expression 
Cloning of the genes or their corresponding 
cDNAs encoding the enzymes for BH4 metabolism 
will have many beneficial consequences such as the 
possibility to overproduce the proteins and purify 
them in large quantities for enzymatic and structural 
studies, and antibody production. Tn addition, for 
the defects described for the four enzymes involved 
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in BH4 metabolism (see Figs. 1 and 2), identification 
of mutations on the DNA, responsible for aberrant 
expression or activity in patients, is the basis for 
future understanding of the deficiency on a molecu-
lar level. 
GTPCR the first biosynthetic enzyme for BH.J, 
has been cloned and DNA sequence information 
is available from two different sources: rat liver (35) 
and Escherichia coli (36, 37). The isolated rat liver 
eDNA codes for a putative protein of 241 amino 
acids, whereas the mature protein has the first II 
amino acid residues deleted. Thus, posttranslational 
modification produces a protein of 230 amino acid 
residues with a molecular mass of 25,784 Da. Expres-
sion of the rat GTPCH cDNA in E. coli was repor-
ted to result in an active enzyme, indifferent whether 
it was expressed as the premature form (complete 
eDNA) or as the mature form (38). The mature E. 
,oli GTPCH contains 222 amino acid residues with 
a molecular mass of 24,742 Da. For this enzyme. 
only the starting methionine was found to be remov-
ed. An amino acid alignment of the rat and E. 
,a li sequences revealed homology extending over the 
entire length of the proteins. Overproduction and 
purification of recombinant GTPCH from E. coli 
allowed the crystallization and a preliminary charac-
terization of the X-ray structure (39). Although a 
fragment coding for the human GTPCH was reported 
to be cloned (39), isolating of the complete coding 
region is eagerly awaited in order to study defects 
in patients with reduced GTPCH acitivity. 
The PTPS is the most frequent enzyme acitivity 
that is reduced or missing in patients exhibiting a 
BH4 deficiency. The rat and human liver cDNAs 
have been cloned and sequenced (40-42). The rat 
eDNA codes for a protein of 144 amino acids. The 
first four amino acids are not present in the purified 
enzyme, resulting in a mature rat protein with a 
molecular mass of 15,855 Da. The human liver 
eDNA codes for a protein of 145 residues with an 
estimated molecular weight of 16,387. It exhibits a 
82% identity to the rat amino acid sequence. Since 
the amino terminus of the human PTPS was not 
accessible by Edman degradation due to end block-
ing, the N-tenninus of the mature protein is not 
known. Both, the rat and human cDNA can be 
expressed as an active enzyme in E. coli that makes 
the PTPS easily accessible for further analysis. This 
powerful system made it possible to identifY the first 
mutations in the coding region for PTPS, responsi-
ble for a lowered enzymatic activity in patients with 
BH4 deficiency (41, Thony et al., unpublished). 
A cDNA for SR, the enzyme catalyzing the final 
step in the BH4 biosynthesis. was isolated from rat 
7 
and human liver (43, 44). The rat liver cDNA enco-
des a polypeptide of 262 amino acid residues with 
a molecular mass of 28,169 Da, including the N-ter-
minally acetylated methionine (45). A corresponding 
cDNA isolated from human liver codes for a protein 
of 261 amino acid residues with a molecular mass 
of 28,047 Da. A sequence comparison revealed a 
74% identity between these two enzymes. The rat 
liver enzyme was expressed in E. coli as a translatio-
nal fusion to the N-terminal fragment of ~-galactosi­
dase. Since this resulted in an active SR, it is expec-
ted that also the human enzyme, expressed as a 
non-fusion protein in E. coli, will yield SR activity. 
Alternative reductases to SR, such as AR and CR, 
were found to accomplish at least in vitro the two 
step reduction of the carbonyl groups (compare with 
Fig. 1; (46». These alternative pathways might ac-
count in vivo for the fact that so far no SR deficiency 
was observed in man. Human cDNAs for AR and 
CR have been cloned from several tissues but will 
not be discussed in this article (47-50). 
Following the oxidation of BH4 by the P AH, the 
pterin cofactor is proposed to be efficiently recycled 
in the presence of two proteins. the PHS/PCD and 
DHPR (Fig. 2). Based on the elucidation of the 
complete amino acid sequence of the human and 
rat PHS/PCD (51), the corresponding cDNA was 
cloned from rat and human liver (Thony et af.. un-
published). The native protein was found to be iden-
tical in rat and human, and consists of 103 amino 
acids with a molecular mass of 11,909 Da, The N-
terminally encoded methionine is cleaved off, and 
the second amino acid, the alanine residue. was 
found to be acetylated in the mature protein. Hetero-
logous expression of the cDNA in E. coli yielded 
the activity in a crude extract, thus allowing the pu-
lification of the protei.n in large amounts and ma-
king it accessible to refined biochemical studies. 
Unexpectedly, the PHS/PCD was found to be iden-
tical to the hepatic nuclear dimerization factor for 
the transcription factor HNF-la (52, Thony et al .. 
unpublished). To clarifY the meaning of this finding. 
it will be hepful to have recombinant protein avail-
able, free from any contamination, to perform in vitro 
studies with PAH. In addition, the newly described 
form of hyperphenylalaninemia characterized by 7-
pterin excretion was proposed to be due to a defect 
in PHS/PCD activity (13-17). The isolation of the 
DNA encoding this protein will allow to further in-
vestigate the enzymatic defects in such patients on 
the molecular level. 
The enzyme responsible for the completion of the 
reductive recycling of BH40 DHPR, is thus far the 
protein best studied biochemically and genetically. 
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The DNA sequence encoding the DHPR is avail-
able from rat and human liver (53-55). The rat liver 
cDNA codes for 241 amino acids. However. the 
mature protein appears to have the initiating me-
thionine cleaved off and an acetylated alanine resi-
due on its N-terminus. The molecular weight of 
25,420 (240 amino acids) is very similar to that of the 
human liver enzyme and a sequence alignment 
shows that the two proteins differ only in 10 amino 
acid residues. The human DHPR protein has a 
length of 244 amino acids and a molecular mass 
of 25,760 Da (serine at position 51, (ref. 54» or 
25,774 Da (threonine at position 51, (ref. 55». The 
human enzyme was also reported to be N-terminally 
blocked due to acetylation, however. the mature end 
of the protein is not known. Heterologous expression 
of the entire cDNA encoding the human DHPR 
has been reported and yielded the active enzyme 
in E. coli (56). Moreover, the rat liver DHPR was 
crystallized and its 3-dimensional structure was elu-
cidated (57). Interestingly, it is structurally and me-
chanistically different from the dihydrofolate reduc-
tase. Using PCR technology. mutations on the DNA 
level were detected that caused a change in the poly-
peptide chain (21, 58). Also. RFLP was shown to 
be a useful tool for prenatal diagnosis of DHPR 
deficiency (59). 
In summary, it is remarkable that probably all 
the human metabolic enzymes for BH4 biosynthesis 
and recycling appear to be active when expressed 
in E. coli. Mutations in GTPCH, PTPS, PHSIPCD 
or DHPR can now be easily detected for their ef-
fects on enzyme activity be expressing them in E. 
coli. At the same time. the purification of native and 
also mutant enzymes in large amounts will be facil-
itated. Cells from patients or patients cultured fi-
broblasts contain insufficient material to isolate en-
zymes for such studies. Using PCR-based technology. 
prenatal diagnosis for BH4 deficiency might be in-
troduced as a noninvasive method without any risk 
for the offspring. In the future. one might even con-
sider a completely new area of treatment by using 
gene therapy, i.e. transferring the wild-type gene into 
patients with a BH4-deficiency in order to restore 
the defective gene. Such an approach was shown 
to be feasible in vitro for cells derived from patients 
with a defect in the DHPR gene (60). 
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